Literature DB >> 1385873

Development of [125I]RB104, a potent inhibitor of neutral endopeptidase 24.11, and its use in detecting nanogram quantities of the enzyme by "inhibitor gel electrophoresis".

M C Fournié-Zaluski1, J M Soleilhac, S Turcaud, R Laï-Kuen, P Crine, A Beaumont, B P Roques.   

Abstract

Neutral endopeptidase 24.11, also known as the common acute lymphoblastic leukemia antigen, is a zinc metallopeptidase involved in the inactivation of biologically active peptides, such as the enkephalins and atrial natriuretic peptide. The highly potent radiolabeled inhibitor 2-((3-[125I]iodo-4-hydroxy)phenylmethyl)-4-N-[3-(hydroxyamino-3-oxo-1- phenylmethyl)propyl]amino-4-oxobutanoic acid ([125I]RB104; Ki = 30 pM) has been developed for the enzyme. [125I]RB104 is highly specific, its Ki for another widely distributed zinc peptidase, angiotensin-converting enzyme, being 15 microM. In binding studies using rat brain slices, [125I]RB104 was shown to have a high affinity (Kd = 300 +/- 20 pM) and high specific binding at the Kd concentration (90%). With rat brain homogenates the Kd of [125I]RB104 was 26.8 +/- 0.9 pM, close to the kinetically derived Kd, 7.0 +/- 0.8 pM. Using the inhibitor, we have developed a simple, rapid, and quantitative technique to detect low nanogram quantities of the endopeptidase directly from tissue extracts after SDS/PAGE. The method has been used to show the presence of low quantities of the enzyme in rabbit bone marrow. Apart from its sensitivity, "inhibitor gel electrophoresis" using [125I]RB104 has the advantage over immunohistochemical methods of being able to label the enzyme in all tissues and species. It will therefore be of great value in determining the exact role of this important regulatory peptidase in a number of biological systems. Moreover, this one-step characterization of neutral endopeptidase 24.11 could be extended to other zinc metallopeptidases such as angiotensin-converting enzyme or collagenases, and inhibitors with affinities as high as RB104 could open the way to visualization of zinc metallopeptidases in different tissues by electron microscopy.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1385873      PMCID: PMC49506          DOI: 10.1073/pnas.89.14.6388

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  28 in total

Review 1.  Neutral endopeptidase-24.11 inhibitors: from analgesics to antihypertensives?

Authors:  B P Roques; A Beaumont
Journal:  Trends Pharmacol Sci       Date:  1990-06       Impact factor: 14.819

2.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.

Authors:  M M Bradford
Journal:  Anal Biochem       Date:  1976-05-07       Impact factor: 3.365

3.  An immunohistochemical study of endopeptidase-24.11 ("enkephalinase") in the pig nervous system.

Authors:  R Matsas; A J Kenny; A J Turner
Journal:  Neuroscience       Date:  1986-08       Impact factor: 3.590

4.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

5.  Differences in the structural requirements for selective interaction with neutral metalloendopeptidase (enkephalinase) or angiotensin-converting enzyme. Molecular investigation by use of new thiol inhibitors.

Authors:  M C Fournie-Zaluski; E Lucas; G Waksman; B P Roques
Journal:  Eur J Biochem       Date:  1984-03-01

6.  Neutral endopeptidase 24.11 in rat peripheral tissues: comparative localization by 'ex vivo' and 'in vitro' autoradiography.

Authors:  N Sales; I Dutriez; B Maziere; M Ottaviani; B P Roques
Journal:  Regul Pept       Date:  1991-04-25

7.  Characterisation of two probes for the localisation of enkephalinase in rat brain: [3H]thiorphan and a 125I-labeled monoclonal antibody.

Authors:  H Pollard; S De la Baume; M L Bouthenet; J C Schwartz; P Ronco; P Verroust
Journal:  Eur J Pharmacol       Date:  1987-01-13       Impact factor: 4.432

8.  Effects of monoclonal antibodies raised against the common acute lymphoblastic leukemia antigen on endopeptidase-24.11 activity.

Authors:  A Helene; P E Milhiet; H Haouas; C Boucheix; A Beaumont; B P Roques
Journal:  Biochem Pharmacol       Date:  1992-02-18       Impact factor: 5.858

9.  [Regional distribution of enkephalinase in the rat brain by autoradiography].

Authors:  G Waksman; E Hamel; R Bouboutou; R Besselièvre; M C Fournié-Zaluski; B P Roques
Journal:  C R Acad Sci III       Date:  1984

10.  The enkephalinase inhibitor thiorphan shows antinociceptive activity in mice.

Authors:  B P Roques; M C Fournié-Zaluski; E Soroca; J M Lecomte; B Malfroy; C Llorens; J C Schwartz
Journal:  Nature       Date:  1980-11-20       Impact factor: 49.962

View more
  5 in total

Review 1.  Inhibiting the breakdown of endogenous opioids and cannabinoids to alleviate pain.

Authors:  Bernard P Roques; Marie-Claude Fournié-Zaluski; Michel Wurm
Journal:  Nat Rev Drug Discov       Date:  2012-04       Impact factor: 84.694

2.  Cloning and characterization of Aplysia neutral endopeptidase, a metallo-endopeptidase involved in the extracellular metabolism of neuropeptides in Aplysia californica.

Authors:  J P Zappulla; L Wickham; W Bawab; X F Yang; M V Storozhuk; V F Castellucci; L DesGroseillers
Journal:  J Neurosci       Date:  1999-06-01       Impact factor: 6.167

3.  Characterization of neutral endopeptidase 24.11 in dog glomeruli.

Authors:  C Landry; P Santagata; W Bawab; M C Fournié-Zaluski; B P Roques; P Vinay; P Crine
Journal:  Biochem J       Date:  1993-05-01       Impact factor: 3.857

4.  Identification and characterization of a neutral endopeptidase activity in Aplysia californica.

Authors:  W Bawab; R S Aloyz; P Crine; B P Roques; L DesGroseillers
Journal:  Biochem J       Date:  1993-12-01       Impact factor: 3.857

5.  Binding properties of a highly potent and selective iodinated aminopeptidase N inhibitor appropriate for radioautography.

Authors:  F Noble; N Luciani; S Da Nascimento; R Laï-Kuen; L Bischoff; H Chen; M C Fournié-Zaluski; B P Roques
Journal:  FEBS Lett       Date:  2000-02-04       Impact factor: 4.124

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.